GT Biopharma Statistics

Total Valuation

GT Biopharma has a market cap or net worth of $5.16 million. The enterprise value is -$1.08 million.

Market Cap	5.16M
Enterprise Value	-1.08M

Important Dates

The last earnings date was Thursday, November 14, 2024, after market close.

Earnings Date	Nov 14, 2024
Ex-Dividend Date	n/a

Share Statistics

GT Biopharma has 2.23 million shares outstanding. The number of shares has increased by 31.99% in one year.

Current Share Class	2.23M
Shares Outstanding	2.23M
Shares Change (YoY)	+31.99%
Shares Change (QoQ)	+30.51%
Owned by Insiders (%)	7.14%
Owned by Institutions (%)	65.40%
Float	1.67M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.55
P/TBV Ratio	2.55
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.45

Current Ratio	1.45
Quick Ratio	1.38
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -204.08% and return on invested capital (ROIC) is -141.15%.

Return on Equity (ROE)	-204.08%
Return on Assets (ROA)	-75.14%
Return on Capital (ROIC)	-141.15%
Revenue Per Employee	n/a
Profits Per Employee	-$6.17M
Employee Count	2
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -67.23% in the last 52 weeks. The beta is 0.60, so GT Biopharma's price volatility has been lower than the market average.

Beta (5Y)	0.60
52-Week Price Change	-67.23%
50-Day Moving Average	2.79
200-Day Moving Average	2.85
Relative Strength Index (RSI)	41.23
Average Volume (20 Days)	1,335,743

Short Selling Information

The latest short interest is 89,991, so 4.03% of the outstanding shares have been sold short.

Short Interest	89,991
Short Previous Month	13,718
Short % of Shares Out	4.03%
Short % of Float	5.40%
Short Ratio (days to cover)	0.71

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-13.77M
Pretax Income	-9.64M
Net Income	-12.35M
EBITDA	n/a
EBIT	-13.77M
Earnings Per Share (EPS)	-$7.36

Full Income Statement

Balance Sheet

Cash & Cash Equivalents	6.42M
Total Debt	n/a
Net Cash	6.42M
Net Cash Per Share	$2.87
Equity (Book Value)	2.10M
Book Value Per Share	0.94
Working Capital	2.10M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-12.48M
Capital Expenditures	n/a
Free Cash Flow	-12.48M
FCF Per Share	-$5.59

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

GT Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-31.99%
Shareholder Yield	-31.99%
Earnings Yield	-231.25%
FCF Yield	-233.76%

Analyst Forecast

The average price target for GT Biopharma is $11.00, which is 376.19% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$11.00
Price Target Difference	376.19%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on February 5, 2024. It was a reverse split with a ratio of 0.0333333:1.

Last Split Date	Feb 5, 2024
Split Type	Reverse
Split Ratio	0.0333333:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a